Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024
1. DECIPHERING COMPLICACIES FOR FERROPTOSIS TARGETING THERAPY
1.1 Outline to Ferroptosis Targeting Therapy
1.2 Chronicle & Development of Ferroptosis Targeting Therapy
2. THE CLINICAL NECESSITY FOR FERROPTOSIS TARGETING THERAPY
3. DUAL ROLE OF FERROPTOSIS AS DIAGNOSTIC & PROGNOSTIC BIOMARKER
4. BREAKTHROUGH STRATEGIES FOR FERROPTOSIS MANAGEMENT
4.1 Small Molecules
4.2 Drug Repurposing
4.3 Photodynamic Therapy
4.4 Extracellular Vesicles
5. FERROPTOSIS TARGETING THERAPY BY INDICATIONS: CLINICAL TRENDS & INNOVATIONS
5.1 Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Viral Infections
5.4 Nervous system disorders
5.5 Cardiac Diseases
6. GLOBAL FERROPTOSIS TARGETING THERAPY CLINICAL TRIALS OVERVIEW
6.1 By Phase
6.2 By Country
6.3 By Company
6.4 By Indication
6.5 By Priority Status
7. GLOBAL FERROPTOSIS TARGETING THERAPY CLINICAL TRIALS INSIGHT
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase II
7.5 Phase III
8. GLOBAL FERROPTOSIS TARGETING THERAPY CURRENT MARKET TREND & DEVELOPMENTS
8.1 Current Market Outline
8.2 Future Market Forecast
9. FERROPTOSIS TARGETING THERAPY TREND ANALYSIS BY REGION
9.1 US
9.2 China
9.3 Europe
9.4 South Korea
10. FERROPTOSIS CANDIDATES GRANTED FDA & EMA DESIGNATIONS
11. COMBINATION STRATAGEMS FOR FERROPTOSIS TARGETING THERAPIES
11.1 Combinations with Conventional Therapies
11.2 Combinations with Photodynamic Therapies & Magnetic Field
12. PLATFORMS USED FOR DEVELOPING ADVANCED FERROPTOSIS TARGETING THERAPY
12.1 Ferroptosis & Inflammation Platform
12.2 MIT Platform
12.3 Kojin Ferroptosis Platform
13. GLOBAL FERROPTOSIS TARGETING THERAPY MARKET DYNAMICS
13.1 Market Drivers
13.2 Market Challenges
14. COMPETITIVE LANDSCAPE
14.1 Kojin Therapeutics
14.2 MitoImmune Therapeutics
14.3 Prothegen
14.4 PTC Therapeutics
14.5 Sumitomo
14.6 Tharimmune
Figure 1-1: Role of Ferroptosis in Various Indications
Figure 1-2: Progression of Cell Death
Figure 2-1: Need of Ferroptosis Therapy
Figure 3-1: Ferroptosis Related Protein as Diagnostic & Prognostic Marker
Figure 4-1: Therapeutic Modality for Ferroptosis
Figure 5-1: Plant Products Used to Induce Ferroptosis in Cancer Treatment
Figure 5-2: CNSI-Fe (II) Phase I Study – Initiation & Completion Year
Figure 5-3: N6F11 (Ferroptosis Inducer) – Mode of Action
Figure 5-4: MIT-001 Phase II (NCT05493800) Study – Initiation & Completion Year
Figure 5-5: MIT-001 – Preclinical Stage for Viral Infections
Figure 5-6: Vatiquinone (NCT05515536) Phase III Study – Initiation & Completion Year
Figure 5-7: Utreloxastat Phase II Study – Initiation & Completion Year
Figure 6-1: Global – Ferroptosis Targeting Therapy Clinical Trials By Phase (Numbers), 2024
Figure 6-2: Global – Ferroptosis Targeting Therapy Clinical Trials By Country (Numbers), 2024 - 2030
Figure 6-3: Global – Ferroptosis Targeting Therapy Clinical Trials By Company (Numbers), 2024
Figure 6-4: Global – Ferroptosis Targeting Therapy Clinical Trials By Indication (Numbers), 2024 - 2030
Figure 6-5: Global – Ferroptosis Targeting Therapy Clinical Trials By Priority Status (Numbers), 2024
Figure 8-1: Key Players – Ferroptosis
Figure 8-2: Rudolf Virchow Centre & Julius-Maximilians-Universitдt Wьrzburg Professors received Grant by European Research Council
Figure 8-3: Ferroptosis – Future Market
Figure 9-1: Vatiquinone Phase III (NCT05218655) Study – Initiation & Completion Year
Figure 9-2: Utreloxastat & Vatiquinone Current Development Status
Figure 9-3: Kojin Therapeutics Investors
Figure 9-4: Roche Accelerator, China - Included Keen Therapeutics to Advance Ferroptosis Therapies
Figure 9-5: MIT-001 Phase II (NCT04651634) Study – Initiation & Completion Year
Figure 11-1: Ferroptosis Combinations with Other Therapies
Figure 12-1: Kojin Therapeutics - Ferroptosis Platform
Figure 13-1: Ferroptosis – Market Drivers
Figure 13-2: Ferroptosis – Market Challenges
Table 4-1: Therapeutic Compounds Inducing/Inhibiting Ferroptosis
Table 5-1: Reversing Therapies Resistance by Ferroptosis Inducing Compounds for Cancer
Table 5-2: Role of Ferroptosis in Autoimmune & Inflammatory Disease
Table 5-3: Anti-Ferroptosis Therapeutic Options for Autoimmune & Inflammatory Disease
Table 5-4: Ferroptosis Effector & its Mechanism in Nervous System Disorders
Table 5-5: Role of Ferroptosis in Cardiovascular Diseases
Table 10-1: Ferroptosis Targeting Therapies Granted FDA & EMA Designations
1.1 Outline to Ferroptosis Targeting Therapy
1.2 Chronicle & Development of Ferroptosis Targeting Therapy
2. THE CLINICAL NECESSITY FOR FERROPTOSIS TARGETING THERAPY
3. DUAL ROLE OF FERROPTOSIS AS DIAGNOSTIC & PROGNOSTIC BIOMARKER
4. BREAKTHROUGH STRATEGIES FOR FERROPTOSIS MANAGEMENT
4.1 Small Molecules
4.2 Drug Repurposing
4.3 Photodynamic Therapy
4.4 Extracellular Vesicles
5. FERROPTOSIS TARGETING THERAPY BY INDICATIONS: CLINICAL TRENDS & INNOVATIONS
5.1 Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Viral Infections
5.4 Nervous system disorders
5.5 Cardiac Diseases
6. GLOBAL FERROPTOSIS TARGETING THERAPY CLINICAL TRIALS OVERVIEW
6.1 By Phase
6.2 By Country
6.3 By Company
6.4 By Indication
6.5 By Priority Status
7. GLOBAL FERROPTOSIS TARGETING THERAPY CLINICAL TRIALS INSIGHT
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase II
7.5 Phase III
8. GLOBAL FERROPTOSIS TARGETING THERAPY CURRENT MARKET TREND & DEVELOPMENTS
8.1 Current Market Outline
8.2 Future Market Forecast
9. FERROPTOSIS TARGETING THERAPY TREND ANALYSIS BY REGION
9.1 US
9.2 China
9.3 Europe
9.4 South Korea
10. FERROPTOSIS CANDIDATES GRANTED FDA & EMA DESIGNATIONS
11. COMBINATION STRATAGEMS FOR FERROPTOSIS TARGETING THERAPIES
11.1 Combinations with Conventional Therapies
11.2 Combinations with Photodynamic Therapies & Magnetic Field
12. PLATFORMS USED FOR DEVELOPING ADVANCED FERROPTOSIS TARGETING THERAPY
12.1 Ferroptosis & Inflammation Platform
12.2 MIT Platform
12.3 Kojin Ferroptosis Platform
13. GLOBAL FERROPTOSIS TARGETING THERAPY MARKET DYNAMICS
13.1 Market Drivers
13.2 Market Challenges
14. COMPETITIVE LANDSCAPE
14.1 Kojin Therapeutics
14.2 MitoImmune Therapeutics
14.3 Prothegen
14.4 PTC Therapeutics
14.5 Sumitomo
14.6 Tharimmune
Figure 1-1: Role of Ferroptosis in Various Indications
Figure 1-2: Progression of Cell Death
Figure 2-1: Need of Ferroptosis Therapy
Figure 3-1: Ferroptosis Related Protein as Diagnostic & Prognostic Marker
Figure 4-1: Therapeutic Modality for Ferroptosis
Figure 5-1: Plant Products Used to Induce Ferroptosis in Cancer Treatment
Figure 5-2: CNSI-Fe (II) Phase I Study – Initiation & Completion Year
Figure 5-3: N6F11 (Ferroptosis Inducer) – Mode of Action
Figure 5-4: MIT-001 Phase II (NCT05493800) Study – Initiation & Completion Year
Figure 5-5: MIT-001 – Preclinical Stage for Viral Infections
Figure 5-6: Vatiquinone (NCT05515536) Phase III Study – Initiation & Completion Year
Figure 5-7: Utreloxastat Phase II Study – Initiation & Completion Year
Figure 6-1: Global – Ferroptosis Targeting Therapy Clinical Trials By Phase (Numbers), 2024
Figure 6-2: Global – Ferroptosis Targeting Therapy Clinical Trials By Country (Numbers), 2024 - 2030
Figure 6-3: Global – Ferroptosis Targeting Therapy Clinical Trials By Company (Numbers), 2024
Figure 6-4: Global – Ferroptosis Targeting Therapy Clinical Trials By Indication (Numbers), 2024 - 2030
Figure 6-5: Global – Ferroptosis Targeting Therapy Clinical Trials By Priority Status (Numbers), 2024
Figure 8-1: Key Players – Ferroptosis
Figure 8-2: Rudolf Virchow Centre & Julius-Maximilians-Universitдt Wьrzburg Professors received Grant by European Research Council
Figure 8-3: Ferroptosis – Future Market
Figure 9-1: Vatiquinone Phase III (NCT05218655) Study – Initiation & Completion Year
Figure 9-2: Utreloxastat & Vatiquinone Current Development Status
Figure 9-3: Kojin Therapeutics Investors
Figure 9-4: Roche Accelerator, China - Included Keen Therapeutics to Advance Ferroptosis Therapies
Figure 9-5: MIT-001 Phase II (NCT04651634) Study – Initiation & Completion Year
Figure 11-1: Ferroptosis Combinations with Other Therapies
Figure 12-1: Kojin Therapeutics - Ferroptosis Platform
Figure 13-1: Ferroptosis – Market Drivers
Figure 13-2: Ferroptosis – Market Challenges
Table 4-1: Therapeutic Compounds Inducing/Inhibiting Ferroptosis
Table 5-1: Reversing Therapies Resistance by Ferroptosis Inducing Compounds for Cancer
Table 5-2: Role of Ferroptosis in Autoimmune & Inflammatory Disease
Table 5-3: Anti-Ferroptosis Therapeutic Options for Autoimmune & Inflammatory Disease
Table 5-4: Ferroptosis Effector & its Mechanism in Nervous System Disorders
Table 5-5: Role of Ferroptosis in Cardiovascular Diseases
Table 10-1: Ferroptosis Targeting Therapies Granted FDA & EMA Designations
